Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients

Keiji Yagisawa; Taku Kobayashi; Ryo Ozaki; Shinji Okabayashi; Takahiko Toyonaga; Miki Miura; Mari Hayashida; Eiko Saito; Masaru Nakano; Hajime Matsubara; Tadakazu Hisamatsu; Toshifumi Hibi

doi:10.5217/ir.2018.00078-c1

Articles

Page Path: HOME > Intest Res > Volume 18(3); 2020 > Article

Corrigendum Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients: Keiji Yagisawa¹, Taku Kobayashi², Ryo Ozaki², Shinji Okabayashi², Takahiko Toyonaga², Miki Miura³, Mari Hayashida³, Eiko Saito², Masaru Nakano², Hajime Matsubara¹, Tadakazu Hisamatsu³, Toshifumi Hibi²; Intestinal Research 2020;18(3):343-344.
DOI: https://doi.org/10.5217/ir.2018.00078-c1
Published online: July 20, 2020

¹Department of Pharmacy and Kitasato University Kitasato Institute Hospital, Tokyo, Japan

²Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan

³The Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

4,748 Views
103 Download

Full Article

Download PDF

This corrects the article "Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients" on page 87.

https://doi.org/10.5217/ir.2018.00078

Intest Res 2019;17(1):87-93

In the version of this article initially published, Figure 2 contains errors in the content of the questionnaire.

On page 89, the figure should be corrected as following.

From:

To:

Fig. 2.

(A) Questionnaire 1: acceptability of tablets. (B) Questionnaire 2: acceptability of granules. (C) Questionnaire 3: comparison of tablets and granules. All the original questionnaires were written in Japanese. CR, controlled-release.

Fig. 2.

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients

Intest Res. 2020;18(3):343-344. Published online July 20, 2020

DOI: https://doi.org/10.5217/ir.2018.00078-c1

XML Download

Figure

Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients

Fig. 2. (A) Questionnaire 1: acceptability of tablets. (B) Questionnaire 2: acceptability of granules. (C) Questionnaire 3: comparison of tablets and granules. All the original questionnaires were written in Japanese. CR, controlled-release.

Fig. 2.

Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients